Safety Study of VT7208 in Healthy Volunteers and People With Multiple Sclerosis
Tests the drug VT7208 for safety in healthy volunteers and adults with multiple sclerosis.
Plain-language title generated from the registry record
Registry title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients
Key facts
- Where
- Adelaide, AustraliaSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07085507, who can take part
Where in Australia
- CMAXAdelaide, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vidya Therapeutics Inc
- Trial code
- NCT07085507
- Record updated
- 21 July 2026
- Original description
Part 1 of this study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VT7208 in healthy volunteers.Read full original descriptionShow less
A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Escalation Study in Healthy Participants and an Expansion Cohort in Adult Patients With Multiple Sclerosis to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208
Part 1 of this study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VT7208 in healthy volunteers.
Part 2 of this study will be an open-label, randomized study to characterize the effect of food on the pharmacokinetics of VT7208 in healthy volunteers.
Part 3 of this study will evaluate the safety of VT7208 as monotherapy in patients with MS.
Inclusion: Parts 1 and 2; Age 18-65; Must be in good health with no significant medical history; Willing and able to attend all study visits and comply with study requirements, including lumbar puncture for CSF collection; Able and willing to provide written informed consent; Part 3; Age 18-60; Must be in good health with no significant medical history; MS diagnosis prior to Day 1 in accordance with 2017 McDonald criteria; Willing and able to attend all study visits and comply with study requirements, including lumbar puncture for CSF collection; Able and willing to provide written informed consent.
Exclusion: Known history of illicit drug use or drug abuse, harmful alcohol use (at the -Investigator's discretion), alcoholism, and/or smoking or nicotine-containing product use within 7 days prior to the first dose of study agent; Donation or loss of ≥ 1 unit of whole blood or plasma within 4 weeks prior to dosing; Evidence of clinically significant condition or disease; Any physical or psychological condition that prohibits study completion; History of severe allergic reactions or hypersensitivity.